import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'goal-mapping-framework-matching-peptide-to-outcome',
  title: 'The Goal-Mapping Framework: Matching Peptide to Outcome',
  description:
    'A structured decision framework for selecting research peptides based on experimental objectives. Covers six major research goal categories, compound-to-mechanism mapping, protocol parameters, and common selection errors researchers make when building peptide protocols.',
  category: 'Research Guides',
  readMinutes: 12,
  publishedAt: '2026-07-06',
  ogImage: '/og-image.jpg',
  body: [
    {
      type: 'paragraph',
      text: 'Peptide selection in research protocols is often driven by familiarity ("BPC-157 works for everything"), peer recommendation, or cost — rather than systematic alignment between the experimental objective and the compound\'s mechanism of action. This goal-mapping framework provides a structured approach: start with the biological outcome you want to measure, work backward to the pathway that drives it, and then select the compound best positioned to modulate that pathway in your model.',
    },
    {
      type: 'callout',
      text: 'This framework is designed for research protocol design. All compounds discussed are research peptides for qualified laboratory use only. Nothing in this article constitutes medical advice or clinical guidance.',
    },
    {
      type: 'heading',
      text: 'Why Goal Mapping Matters',
    },
    {
      type: 'paragraph',
      text: 'The research peptide landscape now includes over 200 distinct compounds with documented biological activity. The challenge is not finding a peptide that does something — it is finding the peptide most likely to produce a clean, interpretable effect on your specific endpoint, in your specific model system, at a dose and administration route compatible with your study design.',
    },
    {
      type: 'paragraph',
      text: 'The goal-mapping framework reduces selection errors by forcing explicit articulation of three things before compound selection: (1) the primary outcome endpoint and how you will measure it, (2) the biological mechanism most likely to drive that endpoint, and (3) the receptor/pathway most directly upstream of that mechanism. Compound selection follows from mechanism, not the reverse.',
    },
    {
      type: 'heading',
      text: 'Goal Category 1: Tissue Repair and Musculoskeletal Healing',
    },
    {
      type: 'subheading',
      text: 'Primary Endpoints',
    },
    {
      type: 'list',
      items: [
        'Tendon breaking strength (biomechanical testing)',
        'Histological healing score (neovascularization, cellularity, collagen organization)',
        'Time to functional recovery in behavioral models',
        'Gene expression: VEGF, COL1A1, FGF, PDGF at injury site',
        'Inflammatory cytokine reduction: IL-1β, TNF-α, IL-6 at tissue level',
      ],
    },
    {
      type: 'subheading',
      text: 'Mechanism Mapping',
    },
    {
      type: 'paragraph',
      text: 'Musculoskeletal tissue repair involves four overlapping phases: hemostasis (0–24h), inflammation (1–5d), proliferation (5–21d), and remodeling (21d–2yr). Peptide interventions are most documented in the proliferation and early remodeling phases. The target mechanisms are: angiogenesis for blood vessel ingrowth (VEGF-FAK pathway), cell migration (G-actin remodeling, Wnt signaling), extracellular matrix production (collagen synthesis via lysyl oxidase and TGF-β), and inflammation resolution (NO system, melanocortin receptors).',
    },
    {
      type: 'table',
      headers: ['Goal', 'Key Mechanism', 'Primary Compounds', 'Administration Route'],
      rows: [
        ['Tendon/ligament repair', 'NO-VEGF-FAK angiogenesis + actin remodeling', 'BPC-157 + TB-500', 'SC or IP injection; local injection in some models'],
        ['Muscle crush/tear injury', 'Myofiber regeneration, satellite cell activation', 'BPC-157, Follistatin-344, IGF-1 LR3', 'IP or local injection'],
        ['Bone healing and fracture', 'Osteoblast differentiation, BMP pathway', 'BPC-157, Ipamorelin + CJC-1295, GHK-Cu', 'IP or SC; systemic preferred'],
        ['Cartilage preservation', 'ECM maintenance, anti-inflammatory', 'BPC-157, GHK-Cu, KPV', 'IP or intra-articular in large animal models'],
        ['Wound and skin repair', 'Keratinocyte migration, collagen deposition', 'GHK-Cu, BPC-157, LL-37', 'Topical or SC peri-wound'],
      ],
    },
    {
      type: 'subheading',
      text: 'Common Selection Error',
    },
    {
      type: 'paragraph',
      text: 'Using GH axis peptides (Ipamorelin, CJC-1295) as primary tissue repair agents. While elevated IGF-1 from GH stimulation has anabolic effects on skeletal muscle, these compounds do not directly address the local vascular and matrix repair mechanisms that drive tendon and ligament healing. They may be useful additions to a recovery protocol, but should not replace BPC-157 or TB-500 as the primary mechanistic tools for musculoskeletal repair endpoints.',
    },
    {
      type: 'heading',
      text: 'Goal Category 2: Metabolic Research — Insulin Sensitivity, Body Composition',
    },
    {
      type: 'subheading',
      text: 'Primary Endpoints',
    },
    {
      type: 'list',
      items: [
        'Fasting glucose and insulin (HOMA-IR calculation)',
        'HbA1c or fructosamine in longer studies',
        'Visceral fat mass (DEXA, CT cross-sectional area)',
        'Lean mass preservation or gain',
        'Lipid panel: triglycerides, LDL, HDL',
        'Adipokines: leptin, adiponectin, resistin',
      ],
    },
    {
      type: 'subheading',
      text: 'Mechanism Mapping',
    },
    {
      type: 'paragraph',
      text: 'Metabolic research peptides primarily act through the incretin axis (GLP-1R, GIPR), GH axis (indirect IGF-1 anabolic signaling), and mitochondrial AMPK pathway (MOTS-c). GLP-1R agonism is the most extensively studied and produces glucose-dependent insulin secretion, central appetite suppression via hypothalamic GLP-1R, and peripheral effects including cardiovascular protection and renal tubular glucose reabsorption reduction.',
    },
    {
      type: 'table',
      headers: ['Goal', 'Key Mechanism', 'Primary Compounds', 'Notes'],
      rows: [
        ['Insulin resistance model', 'GLP-1R Gs signaling; AMPK activation', 'Semaglutide, MOTS-c, Tirzepatide', 'HFD or STZ model; dose titration required'],
        ['Visceral fat reduction', 'GIPR + GLP-1R dual agonism; BAT activation', 'Tirzepatide, Retatrutide, AOD-9604', 'Retatrutide adds GcgR thermogenic component'],
        ['Lean mass preservation on caloric deficit', 'GH pulse augmentation; IGF-1 signaling', 'CJC-1295 + Ipamorelin, MK-677', 'Monitor IGF-1 levels as pharmacodynamic marker'],
        ['NASH/hepatic steatosis', 'GLP-1R hepatocyte effects; GcgR lipolysis', 'Semaglutide, Retatrutide', 'Liver histology (NAS score) as primary endpoint'],
        ['Exercise mimetics / metabolic fitness', 'AMPK activation, mitochondrial biogenesis', 'MOTS-c, SS-31', 'AMPK phosphorylation as intermediate endpoint'],
      ],
    },
    {
      type: 'heading',
      text: 'Goal Category 3: Cognitive and Neuroprotective Research',
    },
    {
      type: 'subheading',
      text: 'Primary Endpoints',
    },
    {
      type: 'list',
      items: [
        'Morris Water Maze or Barnes Maze performance (spatial memory)',
        'Novel object recognition test (recognition memory)',
        'Elevated plus maze / open field (anxiety endpoints)',
        'BDNF expression in hippocampus and prefrontal cortex',
        'Neuroinflammatory markers: GFAP, Iba-1, TNF-α in brain tissue',
        'Synaptic density: PSD-95, synaptophysin',
      ],
    },
    {
      type: 'paragraph',
      text: 'Neuroprotective and cognitive-enhancing peptides in research divide into BDNF/neurotrophic factor inducers (Semax, Dihexa), stress-axis modulators (Selank, BPC-157), and mitochondria-targeted compounds with CNS relevance (SS-31, NAD+). Each produces measurable effects on cognition through distinct mechanisms that suggest different experimental models and endpoint selection.',
    },
    {
      type: 'list',
      items: [
        'Semax (and N-Acetyl-Semax-Amidate): Upregulates BDNF in hippocampus and prefrontal cortex; reduces neuroinflammatory cytokines after TBI or ischemic injury. Best-studied endpoint: BDNF gene expression + behavioral tests after injury challenge.',
        'Selank: Potentiates GABAergic transmission; inhibits enkephalin degradation; reduces stress-induced HPA axis activation. Best-studied endpoint: anxiolytic-like behavior in elevated plus maze with concurrent corticosterone measurement.',
        'Dihexa: Potentiates HGF/Met signaling to promote synaptogenesis. Best-studied endpoint: novel object recognition and Morris Water Maze in aging or scopolamine-impaired models.',
        'BPC-157: Documented dopaminergic and serotonergic modulation; reduces drug withdrawal neurotoxicity in animal models. Best-studied endpoint: behavioral recovery in neurotoxicity or addiction models.',
        'SS-31: Mitochondrial cardiolipin stabilization is relevant to neuronal energy in high-metabolic-demand regions. Best-studied endpoint: mitochondrial function markers (OCR/ECAR by Seahorse) and neuroinflammation in TBI models.',
      ],
    },
    {
      type: 'heading',
      text: 'Goal Category 4: Longevity and Anti-Aging Research',
    },
    {
      type: 'subheading',
      text: 'Primary Endpoints',
    },
    {
      type: 'list',
      items: [
        'Epigenetic age (Horvath/GrimAge clock — methylation-based)',
        'Telomere length (qPCR or Southern blot)',
        'Senescent cell burden (SA-β-gal staining, p21, p16 expression)',
        'Mitochondrial function (ATP production, mtDNA integrity)',
        'Inflammatory markers: IL-6, TNF-α, CRP (inflammaging panel)',
        'Cognitive and physical performance correlates (grip strength, coordination tests in rodent models)',
      ],
    },
    {
      type: 'paragraph',
      text: 'Longevity research requires targeting the hallmarks of aging — genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, cellular senescence, and inflammaging — with compounds that have documented activity against one or more of these hallmarks. No single peptide addresses all hallmarks; multi-compound protocols are the norm in serious longevity research design.',
    },
    {
      type: 'table',
      headers: ['Hallmark Targeted', 'Primary Compounds', 'Key Evidence'],
      rows: [
        ['Telomere attrition', 'Epithalon (Epitalon)', 'Telomerase activation in cultured cells; documented telomere lengthening in Khavinson studies'],
        ['Mitochondrial dysfunction', 'SS-31, NAD+, MOTS-c', 'Cardiolipin stabilization (SS-31); sirtuin activation (NAD+); AMPK pathway (MOTS-c)'],
        ['Cellular senescence', 'FOXO4-DRI, GHK-Cu, NAD+', 'FOXO4-DRI senolytic mechanism; GHK-Cu transcriptomic anti-aging in Pickart et al.'],
        ['Inflammaging', 'GHK-Cu, KPV, Thymosin Alpha-1', 'NF-κB suppression; IL-6/TNF-α reduction across multiple models'],
        ['Epigenetic alterations', 'GHK-Cu (NRF2/gene reprogramming), NAD+/sirtuins', 'GHK activates 4000+ gene restorative program; NAD+ → SIRT1 → histone deacetylation'],
        ['Proteostasis decline', 'Rapamycin (mTOR), Spermidine, NAD+', 'mTOR inhibition → autophagy induction → proteostasis restoration'],
      ],
    },
    {
      type: 'heading',
      text: 'Goal Category 5: Immune Research',
    },
    {
      type: 'paragraph',
      text: 'Immune research with peptides covers two distinct objectives: immune activation (enhancing inadequate immune responses, as in immune senescence, chronic infection, or cancer models) and immune modulation (resolving excessive inflammation in autoimmune or inflammatory disease models). The selection depends entirely on which direction the immune system needs to move.',
    },
    {
      type: 'table',
      headers: ['Direction', 'Goal', 'Compounds', 'Key Mechanism'],
      rows: [
        ['Immune activation', 'Enhance T-cell function, NK activity', 'Thymosin Alpha-1, Thymulin, IL-2 (non-peptide reference)', 'TLR activation, T-cell maturation'],
        ['Immune activation', 'Antimicrobial defense', 'LL-37, Defensin-derived peptides', 'Membrane disruption, TLR4 modulation'],
        ['Immune resolution', 'IBD, gut inflammation', 'KPV, BPC-157, LL-37', 'MC1R/MC3R, NF-κB inhibition, epithelial barrier repair'],
        ['Immune resolution', 'Systemic inflammation', 'BPC-157, KPV', 'NO pathway, COX-2 reduction, cytokine modulation'],
        ['Immune senescence', 'Thymus regeneration, aging immunity', 'Thymosin Alpha-1, Thymulin, Epithalon', 'Thymic axis restoration, Treg function'],
      ],
    },
    {
      type: 'heading',
      text: 'Goal Category 6: GH Axis Optimization — Growth, Composition, Recovery',
    },
    {
      type: 'paragraph',
      text: 'GH axis research is often conflated with performance enhancement, but the scientific questions are substantive: how does GH pulse architecture relate to body composition in aging? What is the role of GH axis decline (somatopause) in metabolic deterioration? How do GHRH analogs vs. GHRPs differ in their downstream physiological effects when tested at matched GH-stimulating doses?',
    },
    {
      type: 'list',
      items: [
        'For GH pulse studies: Short-acting GHRH analogs (Sermorelin, CJC-1295 no-DAC) are preferred — they produce pulsatile GH release mimicking physiology. CJC-1295 with DAC produces tonic GH elevation, which is a different physiological state and should not be used in studies designed to test pulsatile GH effects.',
        'For chronic GH axis stimulation studies: CJC-1295-DAC or MK-677 provide sustained elevation without frequent dosing, reducing stress effects in animal models.',
        'For body composition studies: CJC-1295 + Ipamorelin combination produces synergistic GH stimulation. IGF-1, lean mass, and fat mass (DEXA or MRI) are appropriate primary endpoints.',
        'For somatopause reversal in aging models: Sermorelin or Tesamorelin in aged rodents or primates; endpoint set should include GH pulsatility (blood sampling protocol), IGF-1 AUC, body composition, and cognitive/behavioral outcomes.',
        'GHRP-specific effects beyond GH: GHSR-1a is expressed widely — Hexarelin for cardiac protection (CD36 pathway, GH-independent), GHRP-6 for gut motility and appetite, Ipamorelin for adipose selectivity. Design for these requires endpoints beyond IGF-1.',
      ],
    },
    {
      type: 'heading',
      text: 'The Goal-Mapping Decision Tree',
    },
    {
      type: 'paragraph',
      text: 'Apply this sequence before finalizing any peptide selection:',
    },
    {
      type: 'list',
      items: [
        'Step 1 — State the primary endpoint explicitly: What will you measure? How will you measure it? What is your a priori hypothesis about the direction of change?',
        'Step 2 — Identify the biological pathway most upstream of that endpoint. Use the receptor atlas (GPCR family, RTK, intracellular) as a guide.',
        'Step 3 — List all compounds with documented activity on that pathway. Filter by: evidence quality (in vitro only vs. in vivo models), species relevance, and administration route compatibility with your model.',
        'Step 4 — Check for mechanism overlap if stacking: are the selected compounds hitting truly distinct pathways, or are they redundant with convergent downstream effects?',
        'Step 5 — Set your pharmacodynamic marker: an intermediate, measurable biological variable that confirms your compound is producing its expected mechanism in your model system (e.g., elevated plasma GH for GHRH analogs; reduced tissue IL-6 for anti-inflammatory peptides).',
        'Step 6 — Define the dosing and cycling parameters appropriate for the mechanism. GHSR-1a agonists require cycling to prevent tachyphylaxis; GLP-1R agonists do not. Tissue repair peptides in acute injury models may use continuous dosing; longevity protocols often use cycling for regulatory and safety reasons.',
      ],
    },
    {
      type: 'paragraph',
      text: 'The goal-mapping framework will not generate a perfect protocol — research design involves tradeoffs between mechanistic purity, practical constraints, and model limitations. But it prevents the most common failure mode in peptide research design: selecting compounds by reputation rather than by mechanism, and then being unable to interpret results when they do not match expectations.',
    },
    {
      type: 'disclaimer',
      text: 'All compounds referenced are research peptides for qualified laboratory use only. This framework is for experimental design reference only. Nothing herein constitutes medical advice, clinical guidance, or endorsement for human administration.',
    },
  ],
};
